Disc Medicine, Inc. (IRON) SEC Filings & Earnings Calls

Dilution from offering may pressure existing shareholders; no product revenue yet.

“6,000,000 shares offered at $75.00 per share; company is pre-revenue biotech.”

Early-stage data; small sample size (n=13 for efficacy); longer-term safety and efficacy data needed.

“Data cut with n=13 patients completing 26 weeks; ongoing trial with additional cohorts.”

Clinical-stage company with no approved products; net loss increasing as pipeline advances.

“Net loss was $59.5 million for the three months ended June 30, 2026, as compared to $55.2 million for the three months ended June 30, 2025.” · word for word

Bitopertin previously received CRL from FDA; APOLLO trial success is critical.

“Completed Type A meeting with the FDA to discuss the CRL for bitopertin” · word for word

No approved products; no revenue

“We have no products approved for commercial sale and have not generated any revenue from product sales.” · word for word

Increasing net losses

“Net loss was $59.5 million and $123.0 million for the three and six months ended June 30, 2026, respectively.”

Increased debt obligations; minimum cash covenant deferred to 2028.

“amended the minimum cash covenant terms to provide for an initial testing date of July 1, 2028”

Clinical trial failure risk: bitopertin Phase 3 data not yet available; regulatory approval uncertain.

“Topline data expected Q4 2026; FDA decision by mid-2027.”

Operating cost escalation: R&D and SG&A expenses rising faster than revenue (none yet), increasing cash burn.

“R&D expenses increased 65% YoY; SG&A increased 93% YoY.”

No approved products or revenue

“We have no products approved for commercial sale and have not generated any revenue from product sales.” · word for word

Clinical trial failure risk

“We have not yet progressed any product candidates through a Phase 3 clinical trial and may be unable to successfully complete any additional clinical trials for any product candidates we develop.” · word for word

Dependence on third-party manufacturers

“We contract with third parties for the manufacture of our product candidates for preclinical development and clinical testing, and expect to continue to do so for commercialization.” · word for word

Clinical-stage biotech with no approved products

“We are a clinical-stage company with no products approved for commercial sale and we have not generated any revenue from product sales to date.” · word for word

Increasing net loss as pipeline advances

“Net Loss (Thousands) ($) 2025: (212,184)”

Dependence on regulatory approval for bitopertin

“New drug application (NDA) for bitopertin ... accepted by the U.S. Food and Drug Administration (FDA) for priority review under the accelerated approval pathway”

Equity dilution from stock-based compensation and offerings

“Strengthened balance sheet through two equity offerings with aggregate net proceeds of approximately $454.4 million” · word for word

FDA complete response letter for bitopertin indicates regulatory setback; restructuring may impair future revenue potential.

“Receipt of a complete response letter from the FDA on February 13, 2026 with respect to the Company's New Drug Application for bitopertin.” · word for word

CRL from FDA for bitopertin; pursuing traditional approval path

“Received Complete Response Letter from FDA in February 2026; Phase 3 APOLLO study ongoing with topline data expected Q4 2026.”

Regulatory setback for lead asset

“the FDA issued a complete response letter, or CRL.”

No revenue and significant operating losses

“We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the near future, if at all.” · word for word

Bitopertin approval delayed; APOLLO study results required; potential for further delays or failure.

“FDA issued CRL; requires APOLLO study results before approval.”

Regulatory pathway uncertain; FDA may require additional clinical endpoints beyond PPIX.

“FDA concluded that the trials did not show evidence of association between percent change in PPIX and sunlight exposure-based endpoints.” · word for word

FDA rejection of bitopertin NDA for EPP; requires new clinical trial with clinical endpoints, delaying potential approval and revenue.

“CRL states 'significant uncertainty that bitopertin will have the effect it purports'; requires evidence from trial(s) demonstrating efficacy based on clinical endpoints.”

Clinical-stage company with no approved products; regulatory and clinical risks high

“Bitopertin NDA under review; multiple Phase 2 studies ongoing; no commercial revenue yet”

Preliminary cash position subject to adjustment upon completion of year-end close

“This estimate is preliminary and is subject to change upon completion of financial statement closing procedures”

Pre-revenue biotech; net loss increasing; R&D and SG&A costs rising.

“Net loss was $62.3 million for Q3 2025 vs $26.6 million in Q3 2024” · word for word

Clinical-stage biotech with no approved products or revenue

“We have no products approved for commercial sale and have not generated any revenue from product sales.” · word for word

Significant operating losses and accumulated deficit

“We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.” · word for word

Material weakness in internal controls

“We have identified a material weakness in our internal controls over financial reporting and may identify additional material weaknesses in the future.” · word for word